couter

AVIRAtea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. (AVIR) sells antiviral drugs for hepatitis C and E, with a focus on oral therapies. The next catalyst is Feb 8, 2027 — Q4 2021 Earnings Release, which will test the company’s ability to deliver on Phase 3 trial results and cash runway guidance.

  • AVIR’s Phase 3 C-BEYOND trial met its primary endpoints, but cash burn remains a concern.
  • The company has a narrow product pipeline, with limited near-term revenue drivers.
  • Clinical trial progress is a key driver, but commercialization risks are high.

The Read

6% on Q1 2026 neutral results and cash burn concerns, then rallied 14% on Q2 earnings and improved cash runway guidance.
Feb 8, 2027 — Q4 2026 Earnings Release
Chart by TradingView

The schedule

  • Mon8Feb
  • Mon10May
  • Mon9Aug
  • Mon8Nov

Past

  • Mon9Nov

    Actual outcome: Bear

    The company reported an EPS actual of -1.95, matching the estimate, but the stock fell below the bear floor. The lack of positive guidance on cash runway and Phase 3 trial progress raised concerns about near-term viability, driving the decline. The price action aligned with the bear scenario as investors reacted to the lack of optimism in the outlook.

    The earnings release will test the company's ability to provide clarity on Phase 3 C-BEYOND trial progress and cash runway sustainability ahead of the pivotal Q4 readout. This will be a critical event for assessing the near-term viability of the HCV program.

  • Wed12Aug

    Actual outcome: Bull · $5.36 at outcome

    AVIR reported Q2 earnings in line with expectations, with an EPS of -0.41 vs. estimate of -0.41. The stock rallied on improved guidance on cash runway and strategic clarity, signaling stability in demand and long-term growth potential. The price surpassed the bull target, reflecting market confidence in the company's path forward despite the neutral earnings report.

    Q2 earnings print with intense focus on remaining cash runway ahead of pivotal Q4 readouts.

  • Tue12May

    Actual outcome: Bear · $4.19 at outcome

    Atea Pharmaceuticals reported in-line Q1 2026 EPS of -$0.57 and confirmed that its Phase 3 C-BEYOND trial remains on track for a mid-2026 readout. Despite the absence of negative clinical updates, the stock faced heavy selling pressure and plunged well below the $5.20 bear floor. The steep decline indicates that investors likely de-risked ahead of the impending binary trial results or harbored underlying concerns regarding the company's cash burn.

    Q1 2026 earnings will be watched mainly for updated cash burn and runway around $5.87, and any incremental color on the Phase 3 C-BEYOND HCV trial; with no revenue, a clean cash update could support a move toward $6.20, while a higher burn or softer timeline communication could see shares drift back toward $6.20.

  • Thu5Mar

    Actual outcome: Bull · $6.16 at outcome

    Atea Pharmaceuticals reported Q4 2025 EPS of -$0.57, meeting analyst estimates. The stock rallied 16.1% and easily surpassed the $4.20 bull target as management outlined significant progress in its late-stage Hepatitis C (HCV) development program, including commercial launch preparations and expected mid-2026 topline results for the C-BEYOND trial. Updates on the newly expanded Hepatitis E virus (HEV) pipeline further bolstered investor confidence in the company's clinical trajectory.

    Official confirmation of the $301.8M cash and investments position as of year-end 2025 (latest data), extending the runway into 2027/2028. This alleviates the near-term dilution risk priced in by older financial reports, allowing focus to shift to clinical milestones.